Diagnostic Value of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain (HER2 ECD) Change in a Patient with Metastatic Recurrent Breast Cancer Resistant to Anti-HER2 Antibody Drugs: A Case Report-Reference-Cited by-同舟云学术

Diagnostic Value of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain (HER2 ECD) Change in a Patient with Metastatic Recurrent Breast Cancer Resistant to Anti-HER2 Antibody Drugs: A Case Report

Published:2017 Issue:6 Volume:42 Page:912-922
ISSN:0385-7883
Container-title:Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
language:en
Short-container-title:JJCS

Author:

Mise Masahiro¹,Nio Marika²,Higaside Shunichi²,Yonenaga Yoshikuni²,Yata Yoshihiro²,Horita Kenta³,Harada Takehisa³,Sakamoto Hitoshi⁴,Wakamiya Makoto⁵,Kurosawa Manabu⁶

Affiliation:

1. Department of Breast Surgery, Kobe City Medical Center West Hospital1

2. Department of Surgery, Nagahama City Hospital

3. Department of Surgery, Kobe City Medical Center West Hospital

4. Department of Respiratory Surgery, Nagahama City Hospital

5. Department of Radiology, Nagahama City Hospital

6. Department of Clinical Pathology, Nagahama City Hospital

Publisher

Japanese College of Surgeons

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

https://www.jstage.jst.go.jp/article/jjcs/42/6/42_912/_pdf

Reference16 articles.

1. 1) Hattori Y, Yoshida A, Yoshida M, et al:Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Pathol Int 65:286-292, 2015

2. 2) Krop IE, Kim SB, Gonzalez-Martin A, et al:Trastuzumab emtansine versus treatment of physicianʼs choice for pretreated HER-positive advanced breast cancer （TH3RESA）:a randomized, open-label, phase 3 trial. Lancet Oncol 15:689-699, 2014

3. 3) Baselga J, Cortes J, Kim SB, et al:Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012

4. 4) Sunil Verm, David Miles, Luca Gianni, et al:Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 367:1783-1791, 2012

5. 5) Junttila TT, Li G, Parsons K, et al:Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356, 2011